Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4561-4568

  Makimura, Chihiro ^a   Arao, Tokuzo ^a   Matsuoka, Hiromichi ^a   Takeda, Masayuki ^a   Kiyota, Hidemi ^a   Tsurutani, Junji ^a   Fujita, Yoshihiko ^a   Matsumoto, Kazuko ^a   Kimura, Hideharu ^a   Otsuka, Masatomo ^a   Koyama, Atsuko ^a   Imamura, Chiyo K ^b   Yamanaka, Takeharu ^c   Tanaka, Kyoko ^d   Nishio, Kazuto ^a   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

^d Osaka Prefecture University   (Japan)

Author keywords

Cytokines; IL 12; MIP 1 ; Morphine; Plasma

Indexed keywords

ALPHA2 INTERFERON; C REACTIVE PROTEIN; CYTOKINE; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MORPHINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER OF UNKNOWN PRIMARY SITE; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; DISEASE MARKER; DRUG MEGADOSE; FEMALE; GALLBLADDER CANCER; HUMAN; KIDNEY CARCINOMA; LEUKOCYTE COUNT; LUNG CANCER; LYMPHOMA; MALE; NEOPLASM; PAIN ASSESSMENT; PANCREAS CANCER; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SKIN CANCER; STOMACH CANCER; THROMBOCYTE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CHEMOKINE CCL3; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-12; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84855170519     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Somogyi AA, Barratt DT and Coller JK: Pharmacogenetics of opioids. Clin Pharmacol Ther 81: 429-444, 2007. (Pubitemid 46364493)
2. Lötsch J, Geisslinger G and Tegeder I: Genetic modulation of the pharmacological treatment of pain. Pharmacol Ther 124: 168-184, 2009.
3. Tremblay J and Hamet P: Genetics of pain, opioids, and opioid responsiveness. Metabolism 59(Suppl 1): S5-8, 2010.
4. Walter C and Lötsch J: Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 146: 270-275, 2009.
5. Fujita K, Ando Y, Yamamoto W, Miya T, Endo H, Sunakawa Y, Araki K, Kodama K, Nagashima F, Ichikawa W, Narabayashi M, Akiyama Y, Kawara K, Shiomi M, Ogata H, Iwasa H, Okazaki Y, Hirose T and Sasaki Y: Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother Pharmacol 65: 251-258, 2010.
6. Rogers TJ, Steele AD, Howard OM and Oppenheim JJ: Bidirectional heterologous desensitization of opioid and chemokine receptors.Ann NY Acad Sci 917: 19-28, 2000.
7. Finley MJ, Happel CM, Kaminsky DE and Rogers TJ: Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression. Cell Immunol 252: 146-154, 2008.
8. de la Cruz-Merino L, Grande-Pulido E, Albero-Tamarit A and Codes-Manuel de Villena ME: Cancer and immune response: old and new evidence for future challenges.Oncologist 13: 1246-1254, 2008.
9. Balakin KV, Ivanenkov YA, Tkachenko SE, Kiselyov AS and Ivachtchenko AV: Regulators of chemokine receptor activity as promising anticancer therapeutics.Curr Cancer Drug Targets 8: 299-340, 2008. (Pubitemid 351881355)
10. Lara-Muñoz C, De Leon SP, Feinstein AR, Puente A and Wells CK: Comparison of three rating scales for measuring subjective phenomena in clinical research. I. Use of experimentally controlled auditory stimuli. Arch Med Res 35: 43-48, 2004. (Pubitemid 38249310)
11. Williamson A and Hoggart B: Pain: a review of three commonly used pain rating scales. J Clin Nurs 14: 798-804, 2005. (Pubitemid 41018435)
12. Swarm R, Abernethy AP, Anghelescu DL, Benedetti C, Blinderman CD, Boston B, Cleeland C, Coy le N, Deleon-Casasola OA, Eilers JG, Ferrell B, Janjan NA, Karver SB, Levy MH, Lynch M, Moryl N, Murphy BA, Nesbit SA, Oakes L, Obbens EA, Paice JA, Rabow MW, Syrjala KL, Urba S and Weinstein SM: NCCN Adult Cancer Pain. Adult cancer pain. J Natl Compr Canc Netw 5: 1046-1086, 2010.
13. Kasahara K, Arao T, Sakai K, Matsumoto K, Sakai A, Kimura H, Sone T, Horiike A, Nishio M, Ohira T, Ikeda N, Yamanaka T, Saijo N and Nishio K: Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma. Clin Cancer Res 16: 4616-4624, 2010.
14. Yamada Y, Arao T, Matsumoto K, Gupta V, Tan W, Fedynyshyn J, Nakajima TE, Shimada Y, Hamaguchi T, Kato K, Taniguchi H, Saito Y, Matsuda T, Moriya Y, Akasu T, Fujita S, Yamamoto S and Nishio K: Plasma concentrations of VCAM-1 and PAI-1: a predictive biomarker for post-operative recurrence in colorectal cancer. Cancer Sci 101: 1886-1890, 2010.
15. Wolpe SD, Davatelis G, Sherry B, Beutler B, Hesse DG, Nguyen HT, Moldawer LL, Nathan CF, Lowry SF and Cerami A: Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med 167: 570-581, 1988. (Pubitemid 18073655)
16. Menten P, Wuyts A and Van Damme J: Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 13: 455-481, 2002. (Pubitemid 35303816)
17. Mahajan SD, Schwartz SA, Aalinkeel R, Chawda RP, Sykes DE and Nair MP: Morphine modulates chemokine gene regulation in normal human astrocytes. Clin Immunol 115: 323-332, 2005. (Pubitemid 40716049)
18. Choi Y, Chuang LF, Lam KM, Kung HF, Wang JM, Osburn BI and Chuang RY: Inhibition of chemokine-induced Chemotaxis of monkey leukocytes by mu-opioid receptor agonists. In Vivo 13: 389-396, 1999. (Pubitemid 30052833)
19. Mahajan SD, Schwartz SA, Shanahan TC, Chawda RP and Nair MP: Morphine regulates gene expression of alpha- and beta-chemokines and their receptors on astroglial cells via the opioid mu receptor. J Immunol 169: 3589-3599, 2002.
20. Zhang N, Rogers TJ, Caterina M and Oppenheim JJ: Proinflammatory chemokines, such as C-C chemokine ligand 3, desensitize mu-opioid receptors on dorsal root ganglia neurons. J Immunol 173: 594-599, 2004. (Pubitemid 38797388)
21. 2+-independent protein kinase Cs mediate heterologous desensitization of leukocyte chemokine receptors by opioid receptors. J Biol Chem 275: 12729-12736, 2003.
22. Labuz D, Berger S, Mousa SA, Zöllner C, Rittner HL, Shaqura MA, Segovia-Silvestre T, Przewlocka B, Stein C and Machelska H: Peripheral antinociceptive effects of exogenous and immune cell-derived endomorphins in prolonged inflammatory pain. J Neurosci 26: 4350-4358, 2006. (Pubitemid 44315394)
23. Rittner HL, Brack A and Stein C: Pain and the immune system. Br J Anaesth 101: 40-44, 2008. (Pubitemid 351881900)